TriangleNCT00940225 · OUTCOME
Progression-Free Survival (PFS) - Randomized Stage, RDT Cohorts Only
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- From initial dose through final study visit up to 44 months
What was measured
Progression Free Survival during the Randomized Stage (Randomized Population)
Groups in this outcome
Randomized Phase - CRPC, Cabozantinib Arm
cabozantinib, 100 mg, po QD, ongoing until progression
Randomized Phase - CRPC, Placebo Arm
placebo 100mg, po QD, ongoing until progression
Randomized Phase - Melanoma, Cabozantinib Arm
cabozantinib, 100 mg, po QD, ongoing until progression
Randomized Phase - Melanoma, Placebo Arm
Placebo, 100mg, po QD, ongoing until progression
Randomized Phase - NSCLC, Cabozantinib Arm
cabozantinib, 100 mg, po QD, ongoing until progression
Randomized Phase - NSCLC, Placebo Arm
placebo, 100mg, po QD, ongoing until progression
Randomized Phase - Pancreatic Cancer, Cabozantinib Arm
cabozantinib, 100 mg, po QD, ongoing until progression
Randomized Phase - Pancreatic Cancer, Placebo Arm
placebo, 100mg, po QD, ongoing until progression
Randomized Phase - Gastric/GEJ, Cabozantinib Arm
cabozantinib, 100 mg, po QD, ongoing until progression
Randomized Phase - Gastric/GEJ , Placebo Arm
placebo, 100mg, po QD, ongoing until progression
Randomized Phase - HCC, Cabozantinib Arm
cabozantinib, 100 mg, po QD, ongoing until progression
Randomized Phase - HCC, Placebo Arm
placebo, 100 mg, po QD, ongoing until progression
Randomized Phase - SCLC, Cabozantinib Arm
cabozantinib, 100 mg, po QD, ongoing until progression
Randomized Phase - SCLC, Placebo Arm
placebo, 100 mg, po QD, ongoing until progression
Randomized Phase - Ovarian Cancer, Cabozantinib Arm
cabozantinib, 100 mg, po QD, ongoing until progression
Randomized Phase - Ovarian Cancer, Placebo Arm
placebo, 100 mg, po QD, ongoing until progression
Randomized Phase - MBC, Cabozantinib Arm
cabozantinib, 100 mg, po QD, ongoing until progression
Randomized Phase - MBC, Placebo Arm
placebo, 100 mg, po QD, ongoing until progression
| Group | Source count |
|---|---|
| Randomized Phase - CRPC, Cabozantinib Arm | 14 |
| Randomized Phase - CRPC, Placebo Arm | 17 |
| Randomized Phase - Melanoma, Cabozantinib Arm | 13 |
| Randomized Phase - Melanoma, Placebo Arm | 13 |
| Randomized Phase - NSCLC, Cabozantinib Arm | 8 |
| Randomized Phase - NSCLC, Placebo Arm | 8 |
| Randomized Phase - Pancreatic Cancer, Cabozantinib Arm | 3 |
| Randomized Phase - Pancreatic Cancer, Placebo Arm | 3 |
| Randomized Phase - Gastric/GEJ, Cabozantinib Arm | 3 |
| Randomized Phase - Gastric/GEJ , Placebo Arm | 2 |
| Randomized Phase - HCC, Cabozantinib Arm | 10 |
| Randomized Phase - HCC, Placebo Arm | 12 |
| Randomized Phase - SCLC, Cabozantinib Arm | 8 |
| Randomized Phase - SCLC, Placebo Arm | 2 |
| Randomized Phase - Ovarian Cancer, Cabozantinib Arm | 7 |
| Randomized Phase - Ovarian Cancer, Placebo Arm | 6 |
| Randomized Phase - MBC, Cabozantinib Arm | 5 |
| Randomized Phase - MBC, Placebo Arm | 5 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Randomized Phase - CRPC, Cabozantinib Arm | 5.5 | Not reported | 4.0 | 8.5 | Not reported |
| Randomized Phase - CRPC, Placebo Arm | 1.4 | Not reported | 1.25 | 2.73 | Not reported |
| Randomized Phase - Melanoma, Cabozantinib Arm | 4.5 | Not reported | 1.8 | 15.4 | Not reported |
| Randomized Phase - Melanoma, Placebo Arm | 2.8 | Not reported | 1.45 | 5.45 | Not reported |
| Randomized Phase - NSCLC, Cabozantinib Arm | 2.4 | Not reported | 1.3 | 2.9 | Not reported |
| Randomized Phase - NSCLC, Placebo Arm | 2.4 | Not reported | 1.4 | 2.7 | Not reported |
| Randomized Phase - Pancreatic Cancer, Cabozantinib Arm | 2.8 | Not reported | 1.5 | 2.8 | Not reported |
| Randomized Phase - Pancreatic Cancer, Placebo Arm | .07 | Not reported | .07 | .07 | Not reported |
| Randomized Phase - Gastric/GEJ, Cabozantinib Arm | NA | Not reported | 2.3 | NA | There was only one out of three subjects evaluated; unable to estimate due to insufficient number of patients within cohort. |
| Randomized Phase - Gastric/GEJ , Placebo Arm | 1.0 | Not reported | .72 | 1.38 | Not reported |
| Randomized Phase - HCC, Cabozantinib Arm | 2.5 | Not reported | 1.3 | 6.8 | Not reported |
| Randomized Phase - HCC, Placebo Arm | 1.4 | Not reported | 1.3 | 4.2 | Not reported |
| Randomized Phase - SCLC, Cabozantinib Arm | 5.5 | Not reported | 1.9 | 6.9 | Not reported |
| Randomized Phase - SCLC, Placebo Arm | 1.5 | Not reported | .85 | 2.23 | Not reported |
| Randomized Phase - Ovarian Cancer, Cabozantinib Arm | 4.9 | Not reported | 3.9 | 13.6 | Not reported |
| Randomized Phase - Ovarian Cancer, Placebo Arm | 1.4 | Not reported | 1.3 | 1.6 | Not reported |
| Randomized Phase - MBC, Cabozantinib Arm | 6.9 | Not reported | 5.1 | 13.5 | Not reported |
| Randomized Phase - MBC, Placebo Arm | 1.1 | Not reported | .7 | 1.3 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 4.0
- upper Limit
- 8.5
- value
- 5.5
- group Id
- OG001
- lower Limit
- 1.25
- upper Limit
- 2.73
- value
- 1.4
- group Id
- OG002
- lower Limit
- 1.8
- upper Limit
- 15.4
- value
- 4.5
- group Id
- OG003
- lower Limit
- 1.45
- upper Limit
- 5.45
- value
- 2.8
- group Id
- OG004
- lower Limit
- 1.3
- upper Limit
- 2.9
- value
- 2.4
- group Id
- OG005
- lower Limit
- 1.4
- upper Limit
- 2.7
- value
- 2.4
- group Id
- OG006
- lower Limit
- 1.5
- upper Limit
- 2.8
- value
- 2.8
- group Id
- OG007
- lower Limit
- .07
- upper Limit
- .07
- value
- .07
- comment
- There was only one out of three subjects evaluated; unable to estimate due to insufficient number of patients within cohort.
- group Id
- OG008
- lower Limit
- 2.3
- upper Limit
- NA
- value
- NA
- group Id
- OG009
- lower Limit
- .72
- upper Limit
- 1.38
- value
- 1.0
- group Id
- OG010
- lower Limit
- 1.3
- upper Limit
- 6.8
- value
- 2.5
- group Id
- OG011
- lower Limit
- 1.3
- upper Limit
- 4.2
- value
- 1.4
- denoms
- counts
- group Id
- OG000
- value
- 14
- group Id
- OG001
- value
- 17
- group Id
- OG002
- value
- 13
- group Id
- OG003
- value
- 13
- group Id
- OG004
- value
- 8
- group Id
- OG005
- value
- 8
- group Id
- OG006
- value
- 3
- group Id
- OG007
- value
- 3
- group Id
- OG008
- value
- 3
- group Id
- OG009
- value
- 2
- group Id
- OG010
- value
- 10
- group Id
- OG011
- value
- 12
- units
- Participants
- description
- Progression Free Survival during the Randomized Stage (Randomized Population)
- dispersion Type
- 95% Confidence Interval
- groups
- description
- cabozantinib, 100 mg, po QD, ongoing until progression
- id
- OG000
- title
- Randomized Phase - CRPC, Cabozantinib Arm
- description
- placebo 100mg, po QD, ongoing until progression
- id
- OG001
- title
- Randomized Phase - CRPC, Placebo Arm
- description
- cabozantinib, 100 mg, po QD, ongoing until progression
- id
- OG002
- title
- Randomized Phase - Melanoma, Cabozantinib Arm
- description
- Placebo, 100mg, po QD, ongoing until progression
- id
- OG003
- title
- Randomized Phase - Melanoma, Placebo Arm
- description
- cabozantinib, 100 mg, po QD, ongoing until progression
- id
- OG004
- title
- Randomized Phase - NSCLC, Cabozantinib Arm
- description
- placebo, 100mg, po QD, ongoing until progression
- id
- OG005
- title
- Randomized Phase - NSCLC, Placebo Arm
- description
- cabozantinib, 100 mg, po QD, ongoing until progression
- id
- OG006
- title
- Randomized Phase - Pancreatic Cancer, Cabozantinib Arm
- description
- placebo, 100mg, po QD, ongoing until progression
- id
- OG007
- title
- Randomized Phase - Pancreatic Cancer, Placebo Arm
- description
- cabozantinib, 100 mg, po QD, ongoing until progression
- id
- OG008
- title
- Randomized Phase - Gastric/GEJ, Cabozantinib Arm
- description
- placebo, 100mg, po QD, ongoing until progression
- id
- OG009
- title
- Randomized Phase - Gastric/GEJ , Placebo Arm
- description
- cabozantinib, 100 mg, po QD, ongoing until progression
- id
- OG010
- title
- Randomized Phase - HCC, Cabozantinib Arm
- description
- placebo, 100 mg, po QD, ongoing until progression
- id
- OG011
- title
- Randomized Phase - HCC, Placebo Arm
- param Type
- MEDIAN
- reporting Status
- POSTED
- time Frame
- From initial dose through final study visit up to 44 months
- title
- Progression-Free Survival (PFS) - Randomized Stage, RDT Cohorts Only
- type
- PRIMARY
- unit Of Measure
- months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice